Urine samples were collected using the midstream clean catch method. Cells from the urine samples were isolated and expanded. The cultured cells were reprogrammed into iPSC lines. Briefly, four small-molecule compounds were introduced during the early stages of reprogramming to improve iPSC production efficiency. These include: 1) CHIR99021, a GSK3b inhibitor that promotes reprogramming; 2) A-83-01, a TGF-b/Activin/Nodal receptor inhibitor, which enhances reprogramming when combined with OCT4 and KLF4; 3) Y27632, a ROCK kinase inhibitor that boosts reprogramming efficiency; and 4) PD0325901, a MEK inhibitor that stabilizes the iPSC state. The iPSC lines were propagated using mTESR1 medium (StemCell Technologies) on dishes coated with Matrigel (Corning Matrigel Matrix Basement Membrane Growth Factor Reduced) and propagated using Dispase (StemCell Technologies). Genomic DNA was extracted from iPSC lines using QIamp DNA Minikit (Qiagen) following the manufacturer instructions. Sequencing libraries were prepared at BGI using standard PCR-free methods. Whole genome sequencing (WGS) was conducted at 5X or 30X coverage at BGI using with 2x100 bp paired reads on a DNBSEQ-G400 sequencer. The FASTQ files generated from the paired-end sequenced fragments were aligned to the human reference genome GRCh37d5 using BWA. Mark duplicate was performed using PICARD, and indel realignment was conducted using GATK3, resulting in a BAM file for each individual cell line.